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Abstract
Background and Objectives Entospletinib is a selective,
reversible, adenosine triphosphate-competitive small-
molecule spleen tyrosine kinase (SYK) inhibitor that
blocks B cell receptor-mediated signaling and proliferation
in B lymphocytes. This study evaluated the safety, phar-
macokinetics, and pharmacodynamics of entospletinib in a
double-blind, single/multiple ascending dose study in
healthy volunteers.
Methods In sequential cohorts, 120 subjects received
entospletinib (25–1200 mg; fasted) as single or twice-daily
oral doses for 7 days. Along with pharmacokinetics, the
study assessed functional inhibition of ex vivo anti-im-
munoglobulin E-stimulated CD63 expression on basophils
and pervanadate-evoked phosphorylated SYK (pSYK)
Y525. Safety and tolerability were assessed throughout the
study.
Results Entospletinib was generally well-tolerated over a
48-fold dose range. Adverse events (AEs) were generally
mild to moderate, with no AE-driven study drug discon-
tinuations noted. Entospletinib displayed a median plasma
half-life of 9–15 h; entospletinib exposures reached a pla-
teau at C600 mg twice daily (likely due to solubility-lim-
ited absorption) and provided [90% CD63 inhibition at
peak concentrations and [60% inhibition at trough
concentrations (corresponding pSYK inhibition of[70 and
[50%).
Conclusion The overall safety, pharmacokinetics, and
pharmacodynamics profiles of entospletinib support further
clinical evaluation.
Key Points
Entospletinib is a selective oral inhibitor of spleen
tyrosine kinase (SYK) that has been linked to the
pathogenesis of a variety of B cell malignancies,
including chronic lymphocytic leukemia and various
subtypes of non-Hodgkin’s lymphoma.
When administered in single or multiple oral doses
in healthy adults, entospletinib monotherapy is
generally well-tolerated.
Entospletinib displays a median plasma half-life of
9–15 h; exposures plateau at C600 mg twice-daily
doses, which provides[50% coverage at trough
concentrations (based on CD63/phosphorylated SYK
biomarker assessment).
1 Introduction
Spleen tyrosine kinase (SYK) is a non-receptor, cytoplas-
mic protein tyrosine kinase that is predominantly expressed
in cells of hematopoietic lineage. It is an important medi-
ator of immunoreceptor signaling in macrophages, neu-
trophils, mast cells, and B cells.
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In B lymphocytes, antigen-mediated stimulation of the
B cell receptor (BCR) results in the recruitment and
phosphorylation of various kinases, including SYK. Phos-
phorylation of SYK (pSYK) leads to the activation and
amplification of downstream receptor signaling and likely
plays a role in chemokine signaling and cellular responses
such as proliferation, survival, differentiation, and apop-
tosis [1, 2].
Uncontrolled BCR signaling via SYK has been impli-
cated in the pathogenesis of several common B cell
malignancies, including chronic lymphocytic leukemia
(CLL), diffuse large B cell lymphoma (DLBCL), follic-
ular lymphoma (FL), mantle cell lymphoma (MCL),
marginal zone lymphoma, and B-lineage acute lym-
phoblastic leukemia. Given the vital role of SYK in BCR
signaling, inhibitors of SYK activity are an attractive
therapeutic option for hematopoietic B cell lymphomas
and other non-Hodgkin’s lymphoma histologies, where
SYK inhibition would prevent BCR-mediated signaling
and therefore prevent the uncontrolled growth of lym-
phoma cells [3, 4].
A number of molecules targeting the SYK pathway for
allergic, autoimmune, and neoplastic disorders are cur-
rently in various stages of development. These include
adenosine triphosphate (ATP)-binding site inhibitors (fos-
tamatinib, CG14979, and P505-15), P-site inhibitors (C-
61), antisense oligonucleotides, and small-interfering
RNAs [5].
Clinical investigation of fostamatinib, the prodrug of
SYK inhibitor R406, in B cell malignancies demonstrated
responses in CLL/small lymphocyte leukemia (overall
response rate [ORR] 55%), DLBCL (ORR 22%), MCL
(ORR 11%), and FL (ORR 10%) following doses of 200 or
250 mg twice daily. Reported toxicities included diarrhea,
nausea, hypertension, cytopenias, and fatigue, which lim-
ited dosing and have been partially attributed to off-target
effects, including the inhibition of multiple kinases in
addition to SYK [6].
Entospletinib (GS-9973) is a highly selective and oral
SYK inhibitor and is currently undergoing clinical evalu-
ation for autoimmune and oncology indications.
Entospletinib is an ATP-competitive inhibitor of SYK that
disrupts kinase activity with a half-maximal inhibitory
concentration (IC50) of 7.6 nmol/L. A phase II study
involving entospletinib 800 mg twice-daily oral adminis-
tration in subjects with relapsed or refractory CLL
(n = 41) showed a progression-free survival (PFS) rate of
70.1% (at 24 weeks), median PFS of 13.8 months, and an
ORR of 61.0%. The most common treatment-emergent
serious adverse events (AEs) included dyspnea, pneumo-
nia, febrile neutropenia, dehydration, and pyrexia. Com-
mon Grade 3/4 laboratory abnormalities included
neutropenia and reversible alanine aminotransferase/
aspartate aminotransferase elevations. Overall, entosple-
tinib demonstrated clinical activity in subjects with
relapsed or refractory CLL with acceptable toxicity [7].
This paper reports the results of the first-in-human (FIH)
study conducted to evaluate the safety, tolerability, phar-
macokinetics, and pharmacodynamics of entospletinib in
healthy volunteers following single- and multiple-dose oral
administration. The data from this study provided the basis
for subsequent testing of the safety and efficacy of
entospletinib in cancer patients.
Further, this paper describes entospletinib pharmacoki-
netics following multiple-dose administration (doses of
100–1200 mg twice daily) under fed conditions across
additional healthy volunteer studies.
2 Methods
2.1 Ethics
All study protocols were reviewed and approved by the
local institutional review boards (all studies were con-
ducted at Algorithme Pharma, Inc., Laval, QC, Canada).
The studies were conducted in accordance with recognized
international scientific and ethical standards, including but
not limited to the International Conference on Harmo-
nization guideline for Good Clinical Practice and the
original principles embodied in the Declaration of Helsinki.
These standards are consistent with the requirements of the
US Code of Federal Regulations Title 21, Part 312
(21CFR312) and the European Community Directive
2001/20/EC. Written informed consent was obtained from
all participants.
2.2 Study Design
The FIH study was a phase I, randomized, double-blind,
placebo-controlled, single and multiple dose-escalation
study, involving an oral tablet formulation of the mono-
mesylate salt of entospletinib. Subjects received either
single or multiple doses of entospletinib (or placebo) under
fasted conditions (Table 1). The study cohorts were
enrolled in a staggered fashion; single-dose cohorts were
escalated after review of the safety/pharmacokinetic data,
allowing at least 1 week between cohorts, and multiple-
dose cohorts were initiated/escalated after review of safety/
pharmacokinetics from the single-dose cohorts (up to
200 mg) (Electronic Supplementary Material Fig. S1).
Additionally, open-label, multiple-cohort, multiple-dose
studies were conducted that evaluated the pharmacokinet-
ics of entospletinib under fed conditions, i.e., co-adminis-
tration with a standard meal of *400–500 calories with
*10–13 g of fat (Table 1).
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2.3 Subjects
Healthy male and non-pregnant, non-lactating female
subjects aged 18–45 years (inclusive) who were C45 kg in
weight and had a body mass index between 19 and 30 kg/m2
were eligible to participate in the FIH study. Similar
inclusion criteria were used for the fed studies, except that
the eligible enrollment age was increased to 60 years.
In all studies, subjects were required to be free of clin-
ically significant disease or any condition that could jeop-
ardize subject safety or study validity as determined
through the subjects’ medical history, physical examina-
tion, 12-lead electrocardiogram (ECG), and results from
clinical laboratory tests that were performed within
2 weeks prior to the baseline visit (day 0). Prior to
enrollment in the study, all subjects provided informed
written consent. Subjects were ineligible for the studies if
they had used any investigational drug and/or participated
in any clinical trial within 1 month of the first entospletinib
administration. Use of medications, including over-the-
counter medications or herbal products, was not allowed
within 1 week of commencing study drug dosing. Vita-
mins, acetaminophen, hormone replacement therapy, and/
or oral contraceptives were allowed.
2.4 Safety Assessments
Safety was evaluated by assessment of clinical laboratory
tests (hematology profile, chemistry profile, and urinaly-
sis), physical examinations, vital signs, serum pregnancy
tests (for female subjects), 12-lead safety ECGs, and
review of concomitant medications performed at screening,
at baseline (the day before the first study dose), on days
before pharmacokinetic blood sampling, and at various
times during the study. Subjects were monitored for AEs
from baseline to the follow-up visit. AEs were rated as
Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe,
and Grade 4 = life-threatening, according to the Gilead
Sciences’ Modified National Institute of Allergy and
Infectious Diseases (NIAID) Common Toxicity Grading
Scale. Clinical and laboratory AEs were coded (system
organ class, high-level group term, high-level term, pre-
ferred term, and lower-level term) using the Medical Dic-
tionary for Regulatory Activities (MedDRA) Version
15.0.
2.5 Pharmacokinetic Sampling
Serial blood samples were collected pre-dose and over a
12-, 24-, or 48-h period following single or multiple dosing
for assessing the pharmacokinetics of entospletinib across
all studies (Table 1).
2.6 Pharmacodynamic Sampling
Serial blood samples for pharmacodynamics assessment
were collected pre-dose and over a 48-h period following
single or multiple dosing in the FIH study. Whole-blood
samples were utilized for the analysis. The samples were
refrigerated (2–8 C) immediately post collection and
Table 1 Study design and baseline characteristics of phase I clinical studies included in the analyses
Clinical characteristic FIH study (fasted) Fed studies
Dose Single (day 1):a 25, 75,
200, 600, 1200 mg
Multiple (day 1 to day 7, twice daily):b
25, 75, 200, 600, 900, 1200 mg
Multiple (day 1 to day 7, once daily):
900 mg
Multiple (day 1 to day 6, twice daily):c
100, 200, 600, 900, 1200 mg
Population Healthy subjects Healthy subjects Healthy subjects
Subjects (n) 50 70 64
Body weight [median (range); kg] 73 (52–94) 74 (46–101) 70 (52–96)
Age [median (range); years] 36 (19–45) 32 (18–45) 33 (18–57)
Sex [n (%); male] 28 (56) 60 (86) 34 (56)
Race [n (%); white] 41 (82) 62 (89) 54 (84)
FIH first-in-human
a Pharmacokinetic sampling times were conducted at 0, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 18, 24, 28, 36, and 48 h post-dose. Pharma-
codynamic sampling times were conducted at 0, 1, 2, 3, 4, 4.5, 5, 6, 8, 10, 12, 18, 24, 28, and 48 h post-dose
b Pharmacokinetic sampling times for day 1 were conducted at 0, 2, 4, 6, and 12 h post-dose. Pharmacodynamic sampling times for day 1 were
conducted at 0, 2, 4, 6, and 12 h post-dose. Pharmacokinetic sampling times for day 7 were conducted at 0, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12,
16, 18, 20, 24, 28, 36, and 48 h post-dose. Pharmacodynamic sampling times for day 7 were conducted at 0, 1, 2, 3, 4, 4.5, 5, 6, 8, 10, 12, 18, 24,
28, and 48 h post-dose
c Pharmacodynamic sampling times for day 1 were conducted at 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 10, and 12 h post-dose. Pharmaco-
dynamic sampling times for day 6 were conducted at 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 (pre-afternoon dose), 14, 16, 20, and 24 h
post-dose
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stored for up to 24 h. Samples were analyzed within 12 h
of blood collection.
2.7 Bioanalytical Procedures
Entospletinib plasma concentrations were determined with
a validated high-performance liquid chromatogra-
phy/tandem mass spectrometry (MS/MS) bioanalytical
assay (Covance, Madison, WI, USA) [8]. A 50 lL aliquot
of plasma sample was mixed with internal standard and
reconstituted with water/acetonitrile at 50:50 (v:v) fol-
lowed by a liquid/liquid extraction procedure using methyl
tert-butyl ether. Chromatography was performed using a
SynergiTM Polar-RP column (Phenomenex, Torrance, CA,
USA), with mobile phases consisting of formic acid in
water and formic acid in acetonitrile at a flow rate of
0.6 mL/min. The MS/MS precursor ion ? product ion
transition was m/z 412.2 ? m/z 105.1 for entospletinib.
The assay calibration curves were linear, from 1 to
1000 ng/mL (R2 = 0.9070, intercept = 0.000038). Sam-
ples were diluted and re-analyzed if the concentrations
exceeded the curve range.
Dilution quality control (QC) samples were included, at
least in duplicate, for each analytical batch containing
samples requiring dilution. These QC samples were diluted
with blank matrix to the same extent as the most highly
diluted sample. At least one-half of the dilution QC sam-
ples had to be within the range of 85.0–115.0% of theo-
retical for the results of diluted samples to be accepted. The
inter-assay precision range (% relative standard deviation)
was 2.5–5.6, and the inter-assay accuracy range (% relative
error) was -3.2 to 4.3. The stability in frozen matrix was
91 days at -10 to -30 C and 343 days at -60 to -80 C.
2.8 Pharmacodynamic Procedures
2.8.1 CD63 Assay
CD63 surface expression on human whole-blood basophils
was measured using a BasoTestTM Kit (Orpegen Pharma,
Heidelberg, Germany). Briefly, heparinized blood was
incubated at 37 C. Following the incubation, 20 lL of
potentiation buffer B from the BasoTestTM Kit was added
to each well and incubated for an additional 10 min at
37 C. Subsequently, the Fce receptor (FceR) was cross-
linked by the addition of 100 lL of anti-immunoglobulin E
(anti-IgE) to a final concentration of 10 lg/mL and incu-
bated for 20 min at 37 C. Degranulation was arrested by
placing the plate on ice for 5 min. Cells were stained with
20 lL of a staining cocktail, containing CD123-PE/CD63-
FITC/HLA-DR-PerCP and incubated for 20 min on ice. A
total of 2 mL of red cell lysis buffer (Buffer G from the
BasoTestTM Kit) was added to each well, mixed
thoroughly, and incubated at room temperature for 10 min.
The plate was centrifuged and the supernatant discarded.
The cell pellet was washed with 2 mL of washing solution
(Buffer A from the BasoTestTM Kit), and the centrifugation
was repeated. The cells were re-suspended in buffer A and
kept on ice in a 250 lL 96-well U-bottom plate until read
by multicolor flow cytometry on a BDTM FACS LSR II
(Becton, Dickinson and Company, Franklin Lakes, NJ,
USA).
Fluorescence-activated cell sorter (FACS) sampling of
100,000 total events was collected using a high-throughput
screen autosampler. FACS data were collected and
CD123?/human leukocyte antigen–antigen D related
negative (HLA-DR-) basophils were gated. The percent-
ages of CD63? cells in this population were recorded for
each well. Electronic Supplementary Material Fig. S2
provides a representative scatter plot of the CD63? assay
and gate strategy.
2.8.2 Phosphorylated Spleen Tyrosine Kinase (Y525)
Assay
Heparinized blood was incubated in a 96-deep well
V-bottom plate for 1 h at 37 C. Following the incubation,
10 lL of 6 mmol/L pervanadate was added to each well
and incubated for an additional hour at 37 C. Subse-
quently, 750 lL of phosphate-buffered saline was added to
each well and immediately centrifuged at 3300 rpm for
3 min at room temperature. The supernatant was removed
with a 96-well block aspirator (V&P Scientific, Inc., San
Diego, CA, USA). The wash step was repeated and
supernatant was discarded. The cell pellet was placed on
ice and 75 lL of ice-cold 2X cell lysis buffer was added,
mixed immediately, and kept on ice for 30 min prior to
being transferred to 96-well polymerase chain reaction
plates and stored frozen until use. Mesoscale (MSD)
chemiluminescent capture plates were prepared by adding
5 lL of 2 ng/lL N-19 total SYK antibody diluted in Tris-
buffered saline (TBS) to a 96-well goat anti-rabbit small
spot plate. The plate was incubated for 1 h at room tem-
perature. Each well was blocked with 25 lL of blocker
buffer containing 5% rabbit serum for 1 h with shaking on
an orbital shaker. Prior to use, the blocker buffer was
decanted and the wells were washed with 200 lL of
TBS ? 0.2% Tween-20 (TBST). The wash was decanted,
and 25 lL of the whole-blood lysate was added to each
well. The plate was placed on an orbital shaker for 1 h at
room temperature; the supernatant was then decanted into a
10% bleach solution and the plate was washed twice with
200 lL TBST. An antibody cocktail was prepared with
anti-pSYK (Y525) biotinylated antibody (1:1000) plus
streptavidin sulfo-tagged reagent (1:1000) in blocker buffer
containing 5% rabbit serum. A total of 25 lL was added to
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each well and incubated on an orbital shaker for 1 h at
room temperature. The wells were decanted and washed
once with 200 lL TBST. Again, the wells were decanted,
and 150 lL of read buffer was added and read immediately
on the MSD instrument. MSD data were collected, and
electrochemiluminescence readings were recorded for each
well.
2.9 Pharmacokinetic Analysis
The pharmacokinetic parameters of entospletinib were
assessed by non-compartmental methods using a non-linear
curve-fitting software package (Phoenix WinNonlin
Professional, Pharsight Corporation, Mountain View, CA,
USA). The following pharmacokinetic parameters were
evaluated for entospletinib: Cmax (the maximum observed
concentration of the drug), tmax (the time [observed time-
point] of Cmax), t (the estimate of the terminal elimination
half-life of the drug; calculated by dividing the natural log
of 2 by the terminal elimination rate constant [kz; which is
estimated by linear regression of the terminal elimination
phase of the concentration of drug versus time curve]),
AUClast (area under the plasma concentration–time curve
[AUC] from time zero to the time of the last quantifiable
concentration), AUC? (AUC extrapolated to infinity; cal-
culated as AUClast ? Clast/kz [the last observed quantifi-
able concentration of the drug in plasma divided by kz])
(single dose), AUCs (AUC over the dosing interval [s]),
and Ctrough (concentration at the end of the dosing interval)
(multiple dose).
2.10 Pharmacodynamic Analysis
The blood pharmacodynamic measurements conducted for
entospletinib in the FIH study included the number of
CD63? basophils and pSYK (Y525). The changes in
CD63? and pSYK (Y525) expression versus time profiles
were assessed by calculating the following pharmacody-
namic parameters: percentage CD63? basophils and per-
centage pSYK (Y525), reported as normalized to baseline/
pre-dose values.
2.11 Statistical Methods
An evaluable pharmacokinetics population (subjects who
completed at least one pharmacokinetics sampling session
and for whom pharmacokinetic parameters could be cal-
culated), safety population (subjects who received at least
one dose of entospletinib), and pharmacodynamics popu-
lation (subjects who received at least one dose of
entospletinib and had specific laboratory data available for
calculating estimates of pharmacodynamic parameters)
were identified for this study. Pharmacokinetics,
pharmacodynamics, and safety analyses were conducted
based on the corresponding evaluable population.
3 Results
3.1 Subject Demographics
A total of 184 healthy subjects were enrolled and analyzed
for this report. The majority of healthy subjects were male,
white, and of non-Hispanic/Latino ethnicity. The demo-
graphics and other baseline characteristics are shown
in Table 1.
3.2 Safety and Tolerability
Safety results are presented for both the FIH and fed
studies (Table 2). Overall, entospletinib monotherapy was
generally well-tolerated when administered as a single dose
or in multiple doses. No discontinuations due to treatment-
related AEs were reported for the FIH study, but two
subjects in the fed studies (Grade 3 urticaria and moderate
urinary tract infection) discontinued. The majority of AEs
were mild or moderate in severity, with no Grade 4 severity
events. No apparent dose response was observed with any
AE in either the single- or multiple-dose cohorts. The
majority of graded laboratory abnormalities were Grade 1
severity. No subjects experienced serious AEs attributed to
the study drug. No deaths were reported.
3.3 Pharmacokinetics of Entospletinib
3.3.1 Single Dose
The plasma concentration–time profiles of single oral doses
of entospletinib 25, 75, 200, 600, 900, and 1200 mg under
fasted conditions are illustrated in Fig. 1. A summary of
the pharmacokinetic parameters following single-dose
administration is presented in Table 3. Entospletinib was
rapidly absorbed, generally achieving Cmax within 2–3 h
after administration for all doses. After attaining Cmax,
entospletinib plasma concentrations declined with a t of
approximately 9 h at doses C200 mg. The exposures fol-
lowing entospletinib 200 mg increased in a greater-than-
dose-proportional manner compared with those following
75 mg. The exposure increase from 600 to 1200 mg was
less than dose proportional.
3.3.2 Multiple Doses
The plasma concentration–time profiles of entospletinib
following administration of multiple (twice-daily) oral
doses of 25, 75, 200, 600, 900, and 1200 mg in healthy
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volunteers under fasted conditions are presented in Fig. 2.
A summary of the corresponding steady-state (day 7)
pharmacokinetic parameters is presented in Table 4. Fol-
lowing 7 days of multiple dosing, there was an approxi-
mate 2- to 4-fold increase in entospletinib exposure (Cmax
and AUC) on day 7 compared with day 1 (Table 4). Fol-
lowing Cmax (*2–3 h post-dose), plasma concentrations
declined with a t of approximately 9 h at doses B200 mg
twice daily and approximately 14 h at doses [200 mg
twice daily. Steady-state concentrations were achieved
after 3–4 days with twice-daily dosing, which is consistent
with the estimated t. Entospletinib steady-state exposures
increased with increasing doses, ranging from 25 to
600 mg twice daily. Similar to single-dose data, at doses
greater than 600 mg the entospletinib exposure increases
were less than dose proportional, suggesting that exposure
was approaching a plateau.
3.4 Effect of Food
Entospletinib pharmacokinetics were also evaluated fol-
lowing multiple (twice-daily) dosing of entospletinib 100,
200, 600, 900, and 1200 mg under fed conditions. A
summary of the corresponding steady-state pharmacoki-
netic parameters under fed conditions is presented in
Table 5. Absorption of entospletinib under fed conditions
was slower than in the fasted state, with Cmax attained
within 4 h after administration (vs. 2 h under fasted con-
ditions). Entospletinib exposures increased with increasing
doses without any apparent exposure plateau, unlike
exposures in fasted conditions. At a given dose level,
entospletinib exposure was generally lower following fed
versus fasted administration.
3.5 Pharmacodynamics of Entospletinib
The effect of entospletinib on inhibition of ex vivo anti-
IgE-stimulated cell-surface CD63 expression in basophils
after single dosing is illustrated in Electronic Supplemen-
tary Material Fig. S3 and multiple dosing (fasted) is
illustrated in Fig. 3. Overall, inhibition of cell surface
Table 2 Summary of
treatment-related adverse events
occurring in C10% of patients
and Grade C3 laboratory
abnormalities
AEs FIH study (fasted) [n (%)] Fed studies [n (%)]
Single dose Multiple dose
na 40 56 40
AEs (preferred term)b
Headache 5 (12.5) 18 (32.1) 10 (25.0)
Nausea 6 (10.7)
Rhinorrhea 7 (12.5)
Oropharyngeal pain 6 (10.7) 5 (12.5)
Urinary tract infection 1 (2.5)
Laboratory parameter (Grade C3)
ALT 1 (1.8)
AST 1 (1.8)
Creatinine kinase 1 (2.5)
Total bilirubin 1 (1.8)
AEs adverse events, ALT alanine aminotransferase, AST aspartate aminotransferase, FIH first-in-human
a Data from placebo cohorts are excluded
b AEs were mapped (e.g., to system organ class) using the Medical Dictionary for Regulatory Activities
(MedDRA) Version 15.0. AEs/laboratory abnormalities were rated as Grade 1 = mild,
Grade 2 = moderate, Grade 3 = severe, and Grade 4 = life-threatening, according to the Gilead Sci-
ences’ Modified National Institute of Allergy and Infectious Diseases (NIAID) Common Toxicity Grading
Scale
Fig. 1 Mean (±standard deviation) plasma concentrations of
entospletinib following a single oral dose of entospletinib under
fasted conditions. ENTO entospletinib
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CD63 expression (expressed as percentage of baseline)
increased with doses of entospletinib from 25 to 600 mg
following single- or multiple-dose administration. For
doses C600 mg twice daily, the maximal mean inhibition
of CD63 expression peaked at 2–4 h post-dose at C86%
inhibition, with C63% inhibition being maintained at
Ctrough (i.e., 12 h post-dose). The maximal mean inhibition
of CD63 expression was comparable between entospletinib
600, 900, and 1200 mg twice daily.
Electronic Supplementary Material Fig. S4 illustrates
the effect of entospletinib on inhibition of pervanadate-
evoked pSYK-Y525 after single dosing and Fig. 4 illus-
trates multiple dosing (fasted). The baseline levels of
pSYK are shown in Electronic Supplementary Material
Fig. S5. Overall, there was increasing inhibition of pSYK
expression (expressed as percentage of baseline) with
entospletinib doses of 25–600 mg following single- or
multiple-day (twice-daily) administration. For doses
C600 mg twice daily, the maximal mean inhibition of
pSYK expression peaked at 4–5 h post-dose at C72%
inhibition, with C54% inhibition being maintained at
Ctrough (i.e., 12 h post-dose). The maximal mean inhibition
of pSYK expression was comparable between entospletinib
600, 900, and 1200 mg twice daily.
Figure 5 illustrates the exposure–response relationship
between entospletinib concentrations and inhibition of
CD63 expression and pSYK (represented as percentage of
baseline). Entospletinib inhibited both of these parameters
in a concentration-dependent manner with a median
effective concentration (EC50) of 429 and 110 ng/mL for
inhibition of CD63 and pSYK, respectively.
4 Discussion
Entospletinib is a potent, highly selective, oral, small-
molecule inhibitor of SYK that is being developed for the
treatment of hematological malignancies. Entospletinib has
greater than 14-fold selectivity for SYK versus other kinase
targets [8], and hence has the potential for an improved
efficacy and safety profile in patients versus other SYK
inhibitors [5]. This paper reports the results of the FIH
study conducted to evaluate the safety, tolerability, phar-
macokinetics, and pharmacodynamics of entospletinib in
healthy volunteers following single- and multiple-dose oral
administration under fasted conditions. Additionally,
safety, tolerability, and pharmacokinetics following
entospletinib co-administration with food are presented.
Following single and multiple oral administration of
entospletinib under fasted conditions, entospletinib con-
centrations showed a bi-exponential decline. Based on a
terminal t of *9 h, entospletinib is suitable for a twice-
daily dosing regimen. Entospletinib exposures increased in
a less-than-dose-proportional manner at doses [200 mg,
with exposures reaching a plateau at[600 mg twice daily.
The solubility of entospletinib administered as a mono-
mesylate salt is highly pH-dependent: its aqueous solubility
is 3 mg/mL in pH 2 buffer but\0.001 mg/mL at pH C3.0.
Table 3 Mean (% coefficient of variation) pharmacokinetic parameters following single oral administration of entospletinib under fasted
conditions according to dose cohort/group
Parameter 25 mg 75 mg 200 mg 600 mg 1200 mg
n 8 8 8 8 8
Cmax (ng/mL) 42.3 (75.4) 67.8 (83.9) 534.5 (55.6) 778.9 (69.6) 1059.8 (100.7)
tmax (h)
a 2.00 (1.00–3.26) 2.75 (2.00–3.01) 2.00 (2.00–3.50) 2.00 (2.00–3.00) 3.25 (2.75–3.76)
t (h)
a 6.77 (5.28–7.25) 5.31 (3.97–8.65) 9.51 (7.41–10.79) 7.72 (6.78–9.55) 9.59 (7.47–12.13)
AUClast (ngh/mL) 218.3 (85.2) 392.5 (97.8) 4136.3 (64.2) 5834.2 (90.5) 9376.2 (109.1)
AUC? (ngh/mL) 231.1 (80.1) 413.1 (97.6) 4248.7 (64.5) 5957.7 (90.5) 9744.4 (110.6)
AUC? area under the plasma concentration–time curve extrapolated to infinity, calculated as AUClast ? (Clast/kz) [the last observed quantifiable
concentration of the drug in plasma divided by kz], AUClast area under the plasma concentration–time curve from time zero to the time of the last
quantifiable concentration, Cmax maximum observed concentration of drug in plasma, t half-life, tmax time (observed timepoint) of Cmax
a Median value (interquartile range) are reported
Fig. 2 Mean (±standard deviation) steady-state plasma concentra-
tions of entospletinib following multiple oral twice-daily doses of
entospletinib under fasted conditions. ENTO entospletinib
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As such, the absorption of entospletinib may be limited,
particularly at high-dose levels, due to the pH-dependent
solubility as it transits through the intestine during
absorption and thus may explain the plateau in entosple-
tinib exposures.
Further, there was an approximate 3- to 4-fold increase
in entospletinib exposures following multiple doses that
was greater than expected (*2-fold), given an average 9-h
t. Given a slight increase in t between single and mul-
tiple doses, the accumulation may not be completely
attributed to a non-linear systemic clearance mechanism
(e.g., hepatic auto-inhibition), but is also likely due to
increased extent of entospletinib absorption (e.g., auto-in-
hibition of intestinal metabolism/transport). Similar non-
linear accumulation following multiple doses has been
reported for other molecules (e.g., nefazodone; non-linear
accumulation attributed to auto-inhibition of pre-systemic
metabolism) [9]. Additional studies to characterize the
disposition of entospletinib via metabolic/transporter-me-
diated pathways, and non-linear mixed-effects modeling-
based population pharmacokinetic analyses are ongoing to
elucidate the mechanism.
Food and food type can affect the pharmacokinetics of a
drug [10]; therefore, entospletinib pharmacokinetics were
evaluated following co-administration with a high-fat meal.
A dose-dependent reduction in both the absorption rate
(20–70% reduction in Cmax and tmax prolongation by
*2 h) and extent (20–80% reduction in AUC) of
entospletinib exposures was observed under fed conditions
with comparable terminal t, suggesting a decrease in the
total bioavailability of entospletinib without significant
effect on total body clearance. The results may be
explained by the pH-dependent solubility of the mono-
mesylate salt, since food intake can increase pH in the
Table 4 Mean (% coefficient of variation) steady-state pharmacokinetic parameters following multiple (twice-daily) oral administration of
entospletinib under fasted conditions according to dose cohort/group
Parameter 25 mg 75 mg 200 mg 600 mg 900 mg 1200 mg
n 8 8 8 8 8 8
Day 1
Cmax (ng/mL) 23.6 (99.8) 99.8 (74.6) 475.8 (80.3) 1006.6 (77.4) 1033.8 (95.5) 828.2 (109.7)
tmax (h)
a 2.00 (2.00–4.00) 2.00 (2.00–3.00) 2.00 (2.00–2.00) 2.00 (2.00–2.00) 2.00 (2.00–4.00) 2.00 (2.00–3.00)
AUClast (ngh/mL) 115.6 (94.2) 505.3 (79.6) 2254.0 (80.3) 5455.3 (99.7) 5862.5 (100.1) 4185.6 (116.3)
Day 7
Cmax (ng/mL) 57.8 (68.3) 273 (52.1) 1052 (58.6) 2687 (61.1) 2814 (58.3) 3427 (77.1)
tmax (h)
a 2.26 (2.00–2.75) 2.00 (2.00–2.01) 2.27 (2.00–2.50) 2.25 (2.00–3.25) 2.26 (2.00–4.00) 2.75 (2.25–3.50)
Ctrough (ng/mL) 11.9 (64.5) 79.2 (64.0) 380 (63.3) 1242 (65.6) 1473 (67.2) 1471 (79.6)
t (h)
a 8.66 (7.72–9.65) 8.91 (6.72–10.9) 10.0 (8.24–15.7) 15.4 (11.4–20.5) 13.6 (11.6–17.0) 13.9 (9.65–17.0)
AUCs (ngh/mL) 356 (64.8) 1878 (48.2) 7655 (57.4) 21,484 (63.8) 23,895 (61.9) 26,775 (76.8)
AUCs area under the plasma concentration–time curve over the dosing interval, AUClast area under the plasma concentration–time curve from
time zero to the time of the last quantifiable concentration, Cmax maximum observed concentration of drug in plasma, Ctrough observed drug
concentration at the end of the dosing interval, t half-life tmax time (observed timepoint) of Cmax
a Median value (interquartile range) are reported
Table 5 Mean (% coefficient of variation) steady-state pharmacokinetic parameters following multiple (twice-daily) oral administration of
entospletinib under fed conditions according to dose cohort/group
Parameter 100 mg 200 mg 600 mg 900 mg 1200 mg
n 16 8 16 16 7
Cmax (ng/mL) 268 (42.8) 618 (39.6) 1573 (59.8) 2321 (66.0) 2799 (35.9)
tmax (h)
a 4.00 (3.00–4.00) 4.00 (4.00–4.00) 4.00 (3.0–4.0) 4.00 (3.00–4.00) 4.00 (2.50–4.00)
Ctrough (ng/mL) 92.5 (61.8) 201 (66.4) 832 (82.4) 1211 (77.0) 1376 (40.2)
t (h)
a 5.31 (4.27–8.89) 7.74 (5.23–13.0) 12.9 (8.90–14.8) 10.1 (7.46–18.4) 8.95 (7.58–17.7)
AUCs (ngh/mL) 1872 (49.4) 4146 (48.1) 12,689 (69.1) 19,085 (71.0) 22,788 (35.5)
AUCs area under the plasma concentration–time curve over the dosing interval, Cmax maximum observed concentration of drug in plasma, Ctrough
observed drug concentration at the end of the dosing interval, tmax time (observed timepoint) of Cmax, t half-life
A standard meal (*400–500 calories with *10–13 g fat) was used to simulate the fed condition
a Median value (interquartile range) are reported
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gastrointestinal tract [10] (which appears to take prece-
dence over the solubilizing effect of food on entospletinib).
The potency of entospletinib to inhibit SYK downstream
of the FceR was determined in basophils. Crosslinking of
the FceR by anti-IgE induces a phosphorylation of the
immunoreceptor tyrosine-based activation motif (ITAM)
repeat in the FceR, thereby engaging and activating SYK.
The resultant intracellular signaling can be monitored by an
increase in the cell-surface expression of the activation
marker CD63 in basophils [11]. In addition, direct inhibi-
tion of pervanadate-induced SYK phosphorylation (at the
Y525/526 autophosphorylation site) by entospletinib was
evaluated in whole blood.
A good correlation existed between plasma entospletinib
concentrations and the pharmacodynamic measurements;
increasing entospletinib plasma concentrations resulted in
greater suppression of CD63 expression/pSYK, with maximal
inhibition observed at Cmax. Furthermore, pharmacodynamic
inhibition increased with doses of entospletinib up to 600 mg
with comparable maximal inhibition at higher doses.
The estimated EC50 values for inhibition of CD63 and
pSYK were 429 and 110 ng/mL, respectively. Therefore, at
entospletinib doses of 600 mg twice daily or higher, the
steady-state Ctrough levels (approximately [1200 ng/mL)
achieved would provide complete coverage of the pharma-
codynamics EC50 values throughout the 12-h dosing interval.
Based on the results shown previously, and considering the
inter-individual variability, entospletinib 800 mg twice daily
(fasted) was selected as the phase II dose to provide maximum
drug exposure for subjects with malignant disease.
Overall, entospletinib was generally well-tolerated when
administered as a single dose or in multiple doses. At
Fig. 3 Mean (±standard
deviation) inhibition of CD63
pharmacodynamics on day 7
(pharmacokinetic steady state)
following multiple oral twice-
daily doses of entospletinib








day 7 (pharmacokinetic steady
state) following multiple oral




are considered as baseline.
pSYK phosphorylated spleen
tyrosine kinase
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higher doses, some subjects developed modest increases in
indirect bilirubin, consistent with uridine 50-diphospho-
glucuronosyltransferase (UGT) 1A1 inhibition (in vitro
IC50 * 2.5 lmol/L) [8]. Increases in bilirubin were not
associated with other liver function test abnormalities.
Increased transaminases were noted in six subjects,
including two placebo subjects, and tended to be observed
approximately 2 weeks after completion of the study drug.
All elevated total bilirubin and transaminase levels
returned to normal during follow-up.
5 Conclusions
Entospletinib exposures reached a plateau at 600 mg twice
daily under fasted conditions, and provided[50% CD63/
pSYK inhibition at Ctrough. Overall, entospletinib displayed
an acceptable safety profile, supporting further clinical
evaluation in cancer patients.
Acknowledgements The authors thank Impact Communication
Partners, Inc., for editorial assistance in preparing the manuscript. The
results of this study were presented in part at the 2013 Annual
Meeting of American Conference of Cancer Research (AACR) (6–10
April 2013, Washington, DC, USA).
Compliance with Ethical Standards
Ethics This study was performed in compliance with current Good
Clinical Practice (GCP) and was conducted under the review of the
affiliated Institutional Review Board (IRB), whose operations were in
compliance with Section 56 of Title 21 of the Code of Federal
Regulations (CFR). This study was sponsored by Gilead Sciences,
Inc.
Informed Consent Informed consent was obtained from all subjects.
Funding Financial support for this study was provided by Gilead
Sciences, Inc.
Conflict of Interest SR, JAD, FJ, LS, SS, MR, and BPK are
employees of Gilead Sciences, Inc. and may own stock or hold stock
options in the company.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Geahlen RL. SYK and pTyr’d: signaling through the B cell
antigen receptor. Biochim Biophys Acta. 2009;1793:1115–27.
2. Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting SYK
as a treatment for allergic and autoimmune disorders. Expert
Opin Invest Drugs. 2004;13:743–62.
3. Efremov DG, Laurenti L. The SYK kinase as a therapeutic target
in leukemia and lymphoma. Expert Opin Invest Drugs.
2011;20:623–36.
4. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling
pathway as a therapeutic target in CLL. Blood.
2012;120:1175–84.
5. D’Cruz OJ, Uckun FM. Targeting spleen tyrosine kinase (SYK)
for treatment of human disease. J Pharm Drug Deliv Res.
2012;1:1–14.
6. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM,
Lacasce A, et al. Inhibition of Syk with fostamatinib disodium
has significant clinical activity in non-Hodgkin lymphoma and
chronic lymphocytic leukemia. Blood. 2010;115:2578–85.
7. Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M,
et al. An open-label phase 2 trial of entospletinib (GS-9937), a
selective spleen tyrosine kinase inhibitor, in chronic lymphocytic
leukemia. Blood. 2015;125:2336–43.
8. Data on file, Gilead Sciences, Inc. (2012)
9. Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefa-
zodone. Clin Pharmacokinet. 1997;33:260–75.
Fig. 5 Pharmacodynamic response, change from baseline in CD63?
basophils (a) and phosphorylated spleen tyrosine kinase (b) versus
plasma concentrations. ENTO entospletinib, pSYK phosphorylated
spleen tyrosine kinase
204 S. Ramanathan et al.
10. Singh BN. Effects of food on clinical pharmacokinetics. Clin
Pharmacokinet. 1999;37:213–55.
11. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M,
et al. R406, an orally available spleen tyrosine kinase inhibitor
blocks fc receptor signaling and reduces immune complex-me-
diated inflammation [erratum in J Pharmacol Exp Ther.
2013;345:326]. J Pharmacol Exp Ther. 2006;319:998–1008.
PKs and PDs of Entospletinib 205
